Week In Review: Jemicare Out-Licenses Prostate Cancer Therapy To Roche For $650 Million By: TalkMarkets October 15, 2022 at 18:40 PM EDT Deals, financings, trials and approvals on the China biotech/pharma market. Read More >> Related Stocks: Beigene Ltd ADR Cabaletta Bio Inc Roche Holding AG Basel American Depositary Shares
